Moderna's COVID-Flu Combo Vaccine Shows Strong Results in Phase 3 Trials

The new mRNA-1083 vaccine demonstrates higher immune responses compared to standalone vaccines for both viruses.

The combination vaccine generated significantly higher immune responses against three flu strains and SARS-CoV-2.
Phase 3 trials included two groups of 4,000 adults aged 50 and older.
Common side effects were injection site pain, fatigue, muscle aches, and headaches.
Moderna aims to present the data at a medical conference and seek regulatory approval.
Other companies like Pfizer-BioNTech and Novavax are also developing similar combination vaccines.